Bluejay Diagnostics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. on February 28, 2024. The Company is incorporated in Delaware and is classified as an emerging growth company. Its principal executive offices are located in Acton, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter rather than financial performance data.
Material Changes
The material event reported is the receipt of a notification from The Nasdaq Stock Market regarding non-compliance with listing standards. Specifically, the closing bid price for the Company's common stock was below $1.00 for the previous 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days (until August 26, 2024) to regain compliance.
- Compliance Requirement: To cure the deficiency, the closing bid price must be at least $1.00 for a minimum of ten consecutive business days.
- Secondary Compliance Period: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure.
- Delisting Risk: If the Company cannot cure the deficiency during the second compliance period, its common stock will be subject to delisting. The Company may appeal this determination, but there is no assurance of success.
- Management Stance: Management intends to take all reasonable measures to achieve compliance, though there is no assurance of success.
Key Facts for Investor Verification
- Verify the current trading price of Bluejay Diagnostics common stock to assess the likelihood of meeting the $1.00 bid price requirement.
- Monitor the Company's stock price performance over the next 180 days to determine if the ten-day consecutive compliance window is achieved.
- Check for any subsequent filings regarding a reverse stock split or other corporate actions intended to increase the share price.
- Review the Company's market value of publicly held shares to ensure eligibility for a potential second compliance period.